Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25447159 | 0.89 | MAPT (0.59) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL10035934 | 0.84 | POLB (0.59) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25176060 | 0.83 | MAPT (0.60) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25169674 | 0.82 | MAPT (0.66) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25176108 | 0.80 | GFER (0.46) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL18296386 | 0.79 | MAPT (0.59) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27881 | 0.79 | MAPT (0.70) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3555102 | 0.78 | MAPT (0.49) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3552142 | 0.78 | MAPT (0.49) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25197695 | 0.78 | POLB (0.67) | MAPTPOLBCYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | MAPT 4613/4885POLB 791/4885CYP2C9 2913/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | MAPT 2440/4885POLB 698/4885CYP2C9 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.